Advertisement
Advertisement
ILMN
Illumina Inc
226.54
USDSponsored
-11.67
-4.90%
Nov 04, 15:59 UTC -5
Closed
After-Market
227.41
+0.87
+0.38%
Illumina Inc (ILMN) Earnings
ILMN Earnings Reports
Positive Surprise Ratio
ILMN beat 35 of 43 last estimates.
81%
Next Report
Date of Next Report
Feb 03, 2027
Estimate for Q4 26 (Revenue/ EPS)
$1.25B
/$1.56
Implied change from Q3 26 (Revenue/ EPS)
+10.73%
/+8.33%
Implied change from Q4 25 (Revenue/ EPS)
+14.59%
/+15.56%
Illumina Inc earnings per share and revenue
On Oct 29, 2026, ILMN reported earnings of 1.44 USD per share (EPS) for Q3 26, beating the estimate of 1.38 USD, resulting in a 4.10% surprise. Revenue reached 1.13 billion, compared to an expected 1.18 billion, with a -4.10% difference. The market reacted with a -18.64% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 1.56 USD, with revenue projected to reach 1.25 billion USD, implying an increase of 8.33% EPS, and increase of 10.73% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Revolution Medicines, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$2.46
Actual
-$1.90
Surprise
+22.81%
Bio-Rad Laboratories, Inc. Class B
Report Date
Nov 04, 2026 For Q3 26
Estimate
$2.24
Actual
$2.65
Surprise
+17.92%
Cytokinetics Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$1.48
Actual
-$1.37
Surprise
+7.82%
Arcutis Biotherapeutics, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$0.16
Actual
$0.06
Surprise
-64.54%
Viridian Therapeutics, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.81
Surprise
+18.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
$1.15
Actual
$0.81
Surprise
-30.03%
Vir Biotechnology, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.76
Actual
-$0.56
Surprise
+25.20%
Nuvation Bio Inc.
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.12
Actual
-$0.12
Surprise
+4.15%
Myriad Genetics Inc
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+46.08%
Nuvectis Pharma, Inc. Common Stock
Report Date
Nov 04, 2026 For Q3 26
Estimate
-$0.24
Actual
-$1.02
Surprise
-313.79%
FAQ
What were Illumina Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Illumina Inc reported EPS of $1.44, beating estimates by 4.1%, and revenue of $1.13B, -4.1% below expectations.
How did the market react to Illumina Inc's Q3 2026 earnings?
The stock price moved down -18.64%, changed from $290.06 before the earnings release to $235.99 the day after.
When is Illumina Inc expected to report next?
The next earning report is scheduled for Feb 03, 2027.
What are the forecasts for Illumina Inc's next earnings report?
Based on --
analysts, Illumina Inc is expected to report EPS of $1.56 and revenue of $1.25B for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.